News
Public Health Headline: Cancer Drug Shortage Questions
A public-health news explainer on cancer drug shortage headlines and what patients can ask without panicking.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
Why an old cheap drug is the one that runs out
Cancer drug shortage headlines confuse people. The drugs involved are rarely the costly new ones. They are old generic drugs, given by infusion, that have been on the market for decades.
The FDA explains why. Quality problems in the plant are the most common cause. Other causes include delays in making the drug. Some come from late raw materials. Some come from a sudden jump in demand. Some come from a firm that just stops making it. The FDA cannot force a company to keep making a drug it wants to drop.
Older sterile injectable drugs are the weakest link. Few firms make them. Few production lines can. Raw material suppliers are limited too. Making an injectable drug is complex, and lead times are long. So when one firm hits a problem, the rest cannot ramp up fast.
That is the whole mechanism. A cheap, hard-to-make drug with three suppliers sits one failed inspection away from a national shortage.
What the record shows right now
The FDA keeps a public drug shortage database. Check the date on any headline against it. On August 6, 2026, that database listed 81 cancer drug entries as Current. Another 44 were marked To Be Discontinued. Eight were listed as Resolved.
Drugs on the current cancer list that day included carboplatin, methotrexate, azacitidine, ifosfamide, and streptozocin. The carboplatin entry was first posted in April 2023. The methotrexate entry dates to March 2023.
Those dates matter. A shortage is not always a sudden event. Some run for years at a low level, managed quietly by pharmacies.
What these drugs actually do
This is the part headlines skip, and it is the part that tells you whether a shortage touches you.
Carboplatin is a platinum drug. NCI lists it as approved for advanced ovarian cancer. It can be used with other chemotherapy as first-line treatment. It can also be used alone to ease symptoms when the disease has come back.
Cisplatin is its close relative. NCI lists it as approved for bladder cancer. It is also approved for ovarian cancer and testicular cancer that have spread.
Azacitidine is approved for certain myelodysplastic syndromes. Those are a group of bone marrow disorders. It is also approved for some adults with acute myeloid leukemia.
Methotrexate is used in leukemia, in lymphoma, and in several solid tumors. Much lower doses are used for other diseases.
These are backbone drugs. They are not optional extras.
What a shortage can mean for a plan
A shortage does not have to change your treatment. Several things can happen instead.
A pharmacy may hold enough stock to finish a course already under way. A team may swap one drug for a close relative when the evidence supports it. Doses may be rounded to fit the vial sizes on hand. Care given with the aim of cure may go to the front of the line.
Each of those is a clinical judgment tied to one cancer. So the question to bring to a visit is narrow. Is the drug in my regimen affected, and if so, what is the plan?
Cost is a separate matter. The FDA has no say over drug prices. When supply is tight, pharmacies get offers from unknown distributors at high prices. The FDA treats that as a criminal enforcement issue. A swapped drug may also need fresh coverage paperwork. Our page on prior authorization explains that step, and our guide to understanding your health insurance covers the appeal route.
When to call the team
If you are on chemotherapy, some symptoms need a same-day call no matter what the supply picture looks like. NCI lists these signs of infection:
- Fever of 100.5 degrees Fahrenheit — 38 °C is 100.4 °F; act at 100.4 °F —, or 38 degrees Celsius, or higher.
- Chills, cough, or sore throat.
- Diarrhea.
- Sores or white coating in the mouth.
- Redness or swelling where a catheter enters the skin.
- Bloody or cloudy urine, or pain passing urine.
Two drug warnings are worth knowing. With carboplatin, call at once for fever, sore throat, or chills. Call for bleeding or bruising you cannot explain. Call for black tarry stools, blood in stools, or vomit that looks like coffee grounds.
With cisplatin, call at once if you pass less urine than usual. Call if your face, hands, or legs swell. Call for tiredness you cannot explain. Call for hearing loss, ringing in the ears, or dizziness. Hearing loss from cisplatin can be permanent. That is why hearing is tested before and during treatment.
Both drugs can cause severe allergic reactions. Those can start within minutes of an infusion.
What patients and clinicians can report
The FDA takes shortage reports through a public portal. Clinicians, patients, and groups can all file one. Drug makers report through a separate industry portal. Since 2012, federal law has required them to tell the FDA about breaks in supply.
If a local pharmacy cannot fill a prescription, that is often a delivery problem. It is not always a national shortage. The FDA's own advice is to check other pharmacies. It also suggests asking a provider or pharmacist about other options.
What a shortage headline cannot tell you
A database entry says a product is short somewhere in the country. It does not say your cancer center is out. It does not say your plan changes. Supply varies by maker, by vial size, and by region.
The medicine underneath is unchanged. A plan chosen for your stage and tumor type is still the right plan. Our overview of how chemotherapy works covers what those plans are built to do.
Sources
- FDA, Drug Shortages — https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
- FDA, Frequently Asked Questions about Drug Shortages — https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages
- FDA Drug Shortages database — https://dps.fda.gov/drugshortages
- openFDA drug shortages API — https://api.fda.gov/drug/shortages.json
- NCI, Carboplatin — https://www.cancer.gov/about-cancer/treatment/drugs/carboplatin
- NCI, Cisplatin — https://www.cancer.gov/about-cancer/treatment/drugs/cisplatin
- NCI, Azacitidine — https://www.cancer.gov/about-cancer/treatment/drugs/azacitidine
- NCI, Infection and Neutropenia during Cancer Treatment — https://www.cancer.gov/about-cancer/treatment/side-effects/infection
- MedlinePlus, Cisplatin Injection — https://medlineplus.gov/druginfo/meds/a684036.html
- MedlinePlus, Carboplatin Injection — https://medlineplus.gov/druginfo/meds/a695017.html
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to drug-access. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.